Psoriasis is a common condition that can affect all ages. It's thought approximately 2% of the population are affected by this skin condition. It presents as a chronic, scaly rash. It does tend to run in families, so genetics are a factor. However psoriasis can also be influenced by environmental factors. Contrary to some opinions, it is not contagious and the condition isn't caused by allergies. For more information on psoriasis, please visit this page.
The Skin Centre is currently conducting five trials relating to this condition, specifically plaque psoriasis. Only CC-10004-PSOR-010 is recruiting at this time. If you suffer moderate to severe plaque psoriasis and are interested, please contact our Research Manager.
MK-3222-010 (not recruiting)
This 64-week, phase 3, randomised, placebo-controlled, parallel-designed study is designed to evaluate the efficacy and safety/tolerability of subcutaneous SCH900222/MK-322 (Tildrakizumab), followed by an optional long-term safety extension study in patients with moderate to severe chronic plaque psoriasis.
I1F-MC-RHAZ (not recruiting)
This trial is a multi-centre, Phase 3 study with a randomisation, double-blind, placebo-controlled induction dosing period followed by a randomised maintenance dosing period and a long-term extension period. It is designed to evaluate the efficacy and safety of LY2439821(Ixekizumab) in patients with moderate to severe plaque psoriasis.
IMAGINE-2 20210103 (not recruiting)
This trial is a phase 3 study to evaluate the efficacy and safety of induction and maintenance regimens of Brodalumab compared with Placebo and Usterkinumab in patients with moderate to severe plaque psoriasis.
CC-10004-PSOR-008 (not recruiting)
This is a phase 3, multi-centre, randomised, double-blind, placebo-controlled trial. It is designed to determine the efficacy and safety study of Apremilast (CC-1004) in patients with moderate to severe plaque psoriasis.
A Phase 3B, randomised, placebo-controlled, double-blind, double-dummy study of the efficacy and safety of Apremilast (CC-1004), Etanercept and placebo in patients with moderate to severe plaque psoriasis.
Contact us using the form below if you want to participate in these clinical trials